AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33407689 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding support program (90-min class, pamphlet, newsletter, email consultation)
Number of subjects: 141
Study 33407689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet intervention
Number of subjects: 141
Study 33407689 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 141
Study 33020080 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based and self-Assessed measures of health literacy using the European Health Literacy Survey Questionnaire (HLS-EU-Q16) and the Newest Vital Sign (NVS).
Number of subjects: 212
Study 33020080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HLS-EU-Q16 and NVS measures.
Number of subjects: 212
Study 34291988 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% Δ9‐tetrahydrocannabinol (THC) cigarette
Number of subjects: 61
Study 34063322 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurisolo� (20 mg/Kg/die)
Number of subjects: 0
Study 34063322 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurisolo� (400 mg twice daily for 8 weeks)
Number of subjects: 0
Study 33728428 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 44
Study 32424045 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein point-of-care test (CRP-POCT) management strategy
Number of subjects: 40
Study 32424045 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein point-of-care test (CRP-POCT)
Number of subjects: 40
Study 35351531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 2848
Study 35924518 — intervention group
Group type: EXPERIMENTAL
Intervention: PI guidance group
Number of subjects: 65
Study 32586139 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI >30)
Number of subjects: 301
Study 32586139 — intervention group
Group type: COMPARATOR
Intervention: Non-obese patients (BMI ≤30)
Number of subjects: 301
Study 35587723 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% HA2k lotion
Number of subjects: 0
Study 35587723 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control lotion
Number of subjects: 0
Study 35587723 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% HA2k solution
Number of subjects: 0
Study 35587723 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 33934058 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (docetaxel, oxaliplatin, capecitabine; Arm A)
Number of subjects: 55
Study 33934058 — intervention group
Group type: COMPARATOR
Intervention: No induction chemotherapy (Arm B)
Number of subjects: 55
Study 33934058 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (Arm A)
Number of subjects: 55
Study 36163870 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-duration pirtobrutinib plus venetoclax and rituximab
Number of subjects: 600
Study 36163870 — intervention group
Group type: COMPARATOR
Intervention: Venetoclax and rituximab
Number of subjects: 600
Study 33549474 — intervention group
Group type: EXPERIMENTAL
Intervention: MiSight® 1 day (omaifilcon A, CooperVision, Inc.)
Number of subjects: 144
Study 33549474 — intervention group
Group type: COMPARATOR
Intervention: Proclear® 1 day (omaifilcon A, CooperVision, Inc.)
Number of subjects: 144
Study 32735021 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma injections
Number of subjects: 30
Study 32735021 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 30
Study 34362624 — intervention group
Group type: EXPERIMENTAL
Intervention: POC‐PEOF
Number of subjects: 126
Study 34362624 — intervention group
Group type: COMPARATOR
Intervention: FAST
Number of subjects: 126
Study 34016350 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-l-cysteine (NAC) 1000 mg/kg in basal diet
Number of subjects: 120
Study 34016350 — intervention group
Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 120
Study 34016350 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet with NAC
Number of subjects: 120
Study 34116813 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment
Number of subjects: 42
Study 32160043 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 30
Study 32160043 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 30
Study 34674405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) with a composition of 60% fat, 30% protein, and 10% fiber for 8 weeks
Number of subjects: 14
Study 34674405 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 14
Study 34674405 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between serum adiponectin and serum IGF-1 levels
Number of subjects: 14
Study 33973718 — intervention group
Group type: EXPERIMENTAL
Intervention: Community of inquiry‐based blended learning
Number of subjects: 233
Study 33973718 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face teaching (Control)
Number of subjects: 233
Study 32048384 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal consumption of hypnotic drugs
Number of subjects: 249
Study 32048384 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal consumption of anxiolytics
Number of subjects: 249
Study 32048384 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal drug consumption
Number of subjects: 249
Study 32048384 — intervention group
Group type: COMPARATOR
Intervention: Insomnia status
Number of subjects: 249
Study 33827450 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation program
Number of subjects: 340
Study 33827450 — intervention group
Group type: COMPARATOR
Intervention: Usual care and physical activity recommendation
Number of subjects: 340
Study 32799403 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical screening
Number of subjects: 417
Study 32799403 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography screening
Number of subjects: 417
Study 32799403 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive echocardiography
Number of subjects: 417
Study 32799403 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline RHD
Number of subjects: 417
Study 32799403 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite RHD
Number of subjects: 417
Study 35898170 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 1000
Study 35898170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 34432008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 0
Study 34432008 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestin therapy
Number of subjects: 0
Study 34432008 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens alone or combined with estrogen-progestin therapy
Number of subjects: 0
Study 34432008 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal routes of HT administration
Number of subjects: 0
Study 34432008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with natural progesterone
Number of subjects: 0
Study 34432008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of HT
Number of subjects: 0
Study 32055041 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg intravenous)
Number of subjects: 15
Study 32055041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 35747897 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation for 4 months
Number of subjects: 140
Study 35747897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 33857237 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported acne (CDLQI)
Number of subjects: 249
Study 33857237 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported acne (CADI)
Number of subjects: 249
Study 33589311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (Group 1) - home-based dietary plan, counselling by a dietitian.
Number of subjects: 50
Study 33589311 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2) - advised to take a liquid diet of their own choice, including shakes, juices, and milk, along with protein supplements.
Number of subjects: 50
Study 32102557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) using pre-induction chemotherapy (IC) images (Group A)
Number of subjects: 212
Study 32102557 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (IMRT) using post-induction chemotherapy (IC) images (Group B)
Number of subjects: 212
Study 35616226 — intervention group
Group type: EXPERIMENTAL
Intervention: Labels 'episode of back pain', 'lumbar sprain', 'non-specific LBP'
Number of subjects: 1375
Study 35616226 — intervention group
Group type: COMPARATOR
Intervention: Labels 'disc bulge', 'degeneration', 'arthritis'
Number of subjects: 1375
Study 35616226 — intervention group
Group type: EXPERIMENTAL
Intervention: All labels
Number of subjects: 1375
Study 33505717 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Tracking Intervention (ATI)
Number of subjects: 48
Study 33505717 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 32614141 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid chromatography/mass spectrometry (LC-MS) with stable-isotope labeled peptides for detection and quantitation of PSA variant in urine
Number of subjects: 53
Study 36410799 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transdermal glyceryl trinitrate
Number of subjects: 1149
Study 36410799 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 1149
Study 33972367 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 2193
Study 33972367 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2193
Study 35929990 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C (1.5 g/kg/d, intravenously for 3 hours from D1 to D3) plus FOLFOX +/- bevacizumab
Number of subjects: 442
Study 35929990 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX +/- bevacizumab
Number of subjects: 442
Study 35929990 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C plus FOLFOX +/- bevacizumab
Number of subjects: 442
Study 35929990 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 442
Study 34857535 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 52
Study 34857535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 33825412 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Traditional Chinese and Western Medicine (IM)
Number of subjects: 300
Study 33825412 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM)
Number of subjects: 300
Study 33825412 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (WM)
Number of subjects: 300
Study 35105443 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching
Number of subjects: 220
Study 35105443 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo procedure)
Number of subjects: 220
Study 34034274 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 130
Study 34034274 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 130
Study 36336005 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 1115
Study 36336005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1115
Study 33398361 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 23
Study 33398361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvitamin K oral anticoagulants (NOACs)
Number of subjects: 23
Study 34051588 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual simulation-based mobile learning app
Number of subjects: 100
Study 34051588 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper materials
Number of subjects: 100
Study 32384418 — intervention group
Group type: EXPERIMENTAL
Intervention: Kane formula
Number of subjects: 182
Study 32384418 — intervention group
Group type: EXPERIMENTAL
Intervention: EVO 2.0
Number of subjects: 182
Study 32384418 — intervention group
Group type: EXPERIMENTAL
Intervention: Haigis
Number of subjects: 182
Study 32384418 — intervention group
Group type: EXPERIMENTAL
Intervention: Holladay 2
Number of subjects: 182
Study 32384418 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsen
Number of subjects: 182
Study 32384418 — intervention group
Group type: EXPERIMENTAL
Intervention: Holladay 1
Number of subjects: 182
Study 32384418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hill‐RBF 2.0
Number of subjects: 182
Study 32384418 — intervention group
Group type: EXPERIMENTAL
Intervention: SRK/T
Number of subjects: 182
Study 32384418 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrett Universal II
Number of subjects: 182
Study 32384418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoffer Q
Number of subjects: 182
Study 34043064 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 0.5 mg/kg before anesthesia induction
Number of subjects: 85
Study 34043064 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 85
Study 34097062 — intervention group
Group type: EXPERIMENTAL
Intervention: EQW/DAPA (2 mg weekly/10 mg daily)
Number of subjects: 119
Study 34097062 — intervention group
Group type: EXPERIMENTAL
Intervention: PHEN/TPM (7.5 mg/46 mg ER daily)
Number of subjects: 119
Study 34097062 — intervention group
Group type: EXPERIMENTAL
Intervention: EQW (2 mg weekly)
Number of subjects: 119
Study 34097062 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPA (10 mg daily)
Number of subjects: 119
Study 34097062 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPA/MET (10 mg/2000 mg XR daily)
Number of subjects: 119
Study 33497408 — intervention group
Group type: COMPARATOR
Intervention: Pain treatment groups
Number of subjects: 200
Study 33497408 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain level at POD 4
Number of subjects: 200
Study 33497408 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of surgery
Number of subjects: 200
Study 33497408 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 200
Study 33497408 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender and having a paid job
Number of subjects: 200
Study 33497408 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term fear of surgery
Number of subjects: 200
Study 32507434 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 57
Study 32507434 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Acupressure
Number of subjects: 57
Study 32507434 — intervention group
Group type: COMPARATOR
Intervention: Control (Routine cares)
Number of subjects: 57
Study 35750094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 63
Study 35750094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 32650683 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG (4.5 mg/kg thymoglobulin plus cyclosporine [CsA], methotrexate [MTX], and mycophenolate mofetil [MMF])
Number of subjects: 263
Study 32650683 — intervention group
Group type: COMPARATOR
Intervention: Control (CsA, MTX, and MMF)
Number of subjects: 263
Study 32650683 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG
Number of subjects: 263
Study 32650683 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 263
Study 35314257 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg or 25 mg)
Number of subjects: 7020
Study 35314257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 32287075 — intervention group
Group type: EXPERIMENTAL
Intervention: New PD diagnosis
Number of subjects: 8722
Study 35139937 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma gel
Number of subjects: 40
Study 35139937 — intervention group
Group type: COMPARATOR
Intervention: Control group (no platelet-rich plasma gel)
Number of subjects: 40
Study 34967125 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening toothpastes
Number of subjects: 40
Study 34967125 — intervention group
Group type: COMPARATOR
Intervention: Control ligatures (not specified toothpaste)
Number of subjects: 40
Study 33030582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (250 mg/day)
Number of subjects: 101
Study 33030582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium supplementation)
Number of subjects: 101
Study 35914643 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought Suppression
Number of subjects: 139
Study 35914643 — intervention group
Group type: COMPARATOR
Intervention: Focused Distraction
Number of subjects: 139
Study 33334128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled left internal thoracic artery graft
Number of subjects: 109
Study 33334128 — intervention group
Group type: COMPARATOR
Intervention: Skeletonized left internal thoracic artery graft
Number of subjects: 109
Study 33334128 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 109
Study 32293362 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CROSS regimen): paclitaxel 50 mg/m2; carboplatin (AUC = 2), q1w, 5 cycles; concurrent radiotherapy, 41.4 Gy/23 F, over 5 weeks
Number of subjects: 456
Study 32293362 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy: paclitaxel 175 mg/m2; cisplatin 75 mg/m2, q21d, 2 cycles
Number of subjects: 456
Study 36147247 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional economic incentives and motivational interviewing
Number of subjects: 246
Study 36147247 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 246
Study 32054537 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (2 sessions of 60 minutes per week for 8 weeks)
Number of subjects: 80
Study 32054537 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study 35343294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV)
Number of subjects: 180
Study 35343294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional violence
Number of subjects: 180
Study 35343294 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping subscales, social support, and stigma
Number of subjects: 180
Study 35343294 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient adherence to medication and care
Number of subjects: 180
Study 33309478 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfetalness method
Number of subjects: 144
Study 35975806 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomic intervention
Number of subjects: 116
Study 33239219 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (CHO group)
Number of subjects: 75
Study 33239219 — intervention group
Group type: COMPARATOR
Intervention: Flavored water (placebo group)
Number of subjects: 75
Study 33239219 — intervention group
Group type: COMPARATOR
Intervention: Fasting group
Number of subjects: 75
Study 32520820 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid treatment
Number of subjects: 115
Study 32520820 — intervention group
Group type: COMPARATOR
Intervention: Guided internet-delivered pain management treatment
Number of subjects: 115
Study 34775065 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 1 (irradiation device in contact with the skin)
Number of subjects: 41
Study 34775065 — intervention group
Group type: COMPARATOR
Intervention: Protocol 2 (device 3 cm away from the skin)
Number of subjects: 41
Study 34775065 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 41
Study 34775065 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2
Number of subjects: 41
Study 34949169 — intervention group
Group type: EXPERIMENTAL
Intervention: integrated care + fotonovela
Number of subjects: 150
Study 34949169 — intervention group
Group type: COMPARATOR
Intervention: integrated care + standard education
Number of subjects: 150
Study 34240642 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance strength program for hand muscles over 12 weeks
Number of subjects: 60
Study 34240642 — intervention group
Group type: COMPARATOR
Intervention: Control group (single education session)
Number of subjects: 60
Study 36167548 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33772757 — intervention group
Group type: EXPERIMENTAL
Intervention: One year of antiseizure medication (ASM) therapy
Number of subjects: 149
Study 33772757 — intervention group
Group type: EXPERIMENTAL
Intervention: Three years of antiseizure medication (ASM) therapy
Number of subjects: 149
Study 33772757 — intervention group
Group type: EXPERIMENTAL
Intervention: Active epilepsy
Number of subjects: 149
Study 33772757 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of initial ASM treatment
Number of subjects: 149
Study 33772757 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model score
Number of subjects: 149
Study 32544121 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeled-WALANT state (after 10 mL of 1% lidocaine injection)
Number of subjects: 12
Study 32544121 — intervention group
Group type: COMPARATOR
Intervention: Baseline driving (preoperative drive)
Number of subjects: 12
Study 35587504 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 minutes over 10 sessions across 2 weeks)
Number of subjects: 30
Study 35587504 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study 33436117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention studies in 1998
Number of subjects: 2046
Study 33436117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention studies in 2018
Number of subjects: 2046
Study 33436117 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviews in 2018
Number of subjects: 2046
Study 33436117 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviews in 1998
Number of subjects: 2046
Study 33436117 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised trials in 2018
Number of subjects: 2046